Marks Group Wealth Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
Marks Group Wealth Management's CRL Position: Q4 2022 in Review
Marks Group Wealth Management sold out of Charles River Laboratories (CRL) in Q4 2022, closing a stake of 3,690 shares — an estimated $726K sold.
Marks Group Wealth Management first reported a position in CRL in Q4 2019 and held it in 12 quarters. The position peaked at $1.31M in Q3 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.
- Marks Group Wealth Management reported no remaining Charles River Laboratories position as of Q4 2022 after selling out during the quarter.
- Marks Group Wealth Management sold 3,690 Charles River Laboratories shares in Q4 2022, an estimated $726K.
- Marks Group Wealth Management first reported a position in Charles River Laboratories in Q4 2019 and held it in 12 quarters.
- Marks Group Wealth Management's Charles River Laboratories position peaked at $1.31M in Q3 2021.
- 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.
Based on Marks Group Wealth Management's 13F filing for Q4 2022, filed 6 Feb 2023.